Head to Head Comparison: Invivo Therapeutics (NVIV) versus GenMark Diagnostics (GNMK)

Invivo Therapeutics (NASDAQ:NVIV) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Invivo Therapeutics and GenMark Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Invivo Therapeutics N/A -412.40% -181.93%
GenMark Diagnostics -91.58% -87.96% -50.38%

Valuation and Earnings

This table compares Invivo Therapeutics and GenMark Diagnostics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Invivo Therapeutics N/A N/A -$26.74 million ($18.50) -0.11
GenMark Diagnostics $52.52 million 6.52 -$61.85 million ($1.21) -5.07

Invivo Therapeutics has higher earnings, but lower revenue than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Invivo Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Invivo Therapeutics and GenMark Diagnostics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invivo Therapeutics 0 0 0 0 N/A
GenMark Diagnostics 0 1 4 0 2.80

GenMark Diagnostics has a consensus price target of $10.50, suggesting a potential upside of 71.01%. Given GenMark Diagnostics’ higher probable upside, analysts plainly believe GenMark Diagnostics is more favorable than Invivo Therapeutics.

Institutional and Insider Ownership

9.3% of Invivo Therapeutics shares are held by institutional investors. Comparatively, 99.5% of GenMark Diagnostics shares are held by institutional investors. 2.8% of Invivo Therapeutics shares are held by insiders. Comparatively, 7.1% of GenMark Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

GenMark Diagnostics beats Invivo Therapeutics on 8 of the 12 factors compared between the two stocks.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply